Mohammad Reza Ebrahimkhani

Mohammad Reza Ebrahimkhani

Auto-generated profile, based on publicly available information

Mohammad Reza Ebrahimkhani

Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA 15261, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2018 in Nature Methods
Verified
Journal Article
Closed access
PDF file
NYNan Cher Yeo
Nan Cher Yeo
ACAlejandro Chavez
Alejandro Chavez
ALAlissa Lance-Byrne
Alissa Lance-Byrne
YCYingleong Chan
Yingleong Chan
DMDavid Menn
David Menn
GCGeorge Church
George Church

7 September 2015 in Nature Methods
Verified
Journal Article
Open access
PDF file
SKSamira Kiani
Samira Kiani
ACAlejandro Chavez
Alejandro Chavez
MTMarcelle Tuttle
Marcelle Tuttle
RHRichard N Hall
Richard N Hall
RCRaj Chari
Raj Chari
GCGeorge Church
George Church
The length of a single guide RNA (gRNA) determines the function of Cas9. In this study 20-nt gRNAs allowed nuclease activity and genome editing, whereas 14-nt gRNAs mediated transcriptional activation or repression. We demonstrate that by altering the length of Cas9-associated guide RNA (gRNA) we were able to control Cas9 nuclease activity and simultaneously perform genome editing and transcriptional regulation with a single Cas9 protein. We exploited these principles to engineer mammalian synthetic circuits with combined transcriptional regulation and kill functions governed by a single multifunctional Cas9 protein.

27 November 2011 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MEMohammad R Ebrahimkhani
Mohammad R Ebrahimkhani
FOFiona Oakley
Fiona Oakley
LMLindsay B Murphy
Lindsay B Murphy
JMJelena Mann
Jelena Mann
AMAnna Moles
Anna Moles
DMDerek A Mann
Derek A Mann

23 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
SFShayesteh R. Ferdosi
Shayesteh R. Ferdosi
RERadwa Ewaisha
Radwa Ewaisha
FMFarzaneh Moghadam
Farzaneh Moghadam
SKSri Krishna
Sri Krishna
JPJin G Park
Jin G Park
KAKaren S. Anderson
Karen S. Anderson
The CRISPR-Cas9 system has raised hopes for developing personalized gene therapies for complex diseases. Its application for genetic and epigenetic therapies in humans raises concerns over immunogenicity of the bacterially derived Cas9 protein. Here we detect antibodies to Streptococcus pyogenes Cas9 (SpCas9) in at least 5% of 143 healthy individuals. We also report pre-existing human CD8+T cell immunity in the majority of healthy individuals screened. We identify two immunodominant SpCas9 T cell epitopes for HLA-A*02:01 using an enhanced prediction algorithm that incorporates T cell receptor contact residue hydrophobicity and HLA binding and evaluated them by T cell assays using healthy donor PBMCs. In a proof-of-principle study, we demonstrate that Cas9 protein can be modified to eliminate immunodominant epitopes through targeted mutation while preserving its function and specificity. Our study highlights the problem of pre-existing immunity against CRISPR-associated nucleases and offers a potential solution to mitigate the T cell immune response.

5 May 2014 in Nature Methods
Verified
Journal Article
Closed access
PDF file
SKSamira Kiani
Samira Kiani
JBJacob Beal
Jacob Beal
MEMohammad R Ebrahimkhani
Mohammad R Ebrahimkhani
JHJin Huh
Jin Huh
RHRichard N Hall
Richard N Hall
RWRon Weiss
Ron Weiss

6 January 2016 in Nature Communications
Verified
Journal Article
Open access
PGPatrick Guye
Patrick Guye
MEMohammad R. Ebrahimkhani
Mohammad R. Ebrahimkhani
NKNathan Kipniss
Nathan Kipniss
JVJeremy J. Velazquez
Jeremy J. Velazquez
ESEldi Schoenfeld
Eldi Schoenfeld
RWRon Weiss
Ron Weiss
Human induced pluripotent stem cells (hiPSCs) have potential for personalized and regenerative medicine. While most of the methods using these cells have focused on deriving homogenous populations of specialized cells, there has been modest success in producing hiPSC-derived organotypic tissues or organoids. Here we present a novel approach for generating and then co-differentiating hiPSC-derived progenitors. With a genetically engineered pulse of GATA-binding protein 6 (GATA6) expression, we initiate rapid emergence of all three germ layers as a complex function of GATA6 expression levels and tissue context. Within 2 weeks we obtain a complex tissue that recapitulates early developmental processes and exhibits a liver bud-like phenotype, including haematopoietic and stromal cells as well as a neuronal niche. Collectively, our approach demonstrates derivation of complex tissues from hiPSCs using a single autologous hiPSCs as source and generates a range of stromal cells that co-develop with parenchymal cells to form tissues.